Regulation of PDGF production and ERK activation by estrogen is associated with TSC2 gene expression

American Journal of Physiology - Cell Physiology

Volumn 285, Issue 2 54-2, 2003, Pages

  Finlay, G A ^a   Hunter, D S ^b   Walker, C L ^b   Paulson, K E ^c   Fanburg, B L ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell growth; Mitogen activated protein kinase; Tuberin; Tuberous sclerosis complex 2 gene

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 6,7 DIMETHOXY 2 PHENYLQUINOXALINE; ANTIESTROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NEUTRALIZING ANTIBODY; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; SURAMIN; TUBERIN; TYRPHOSTIN; TYRPHOSTIN AG 17; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; GENE; GENETIC TRANSCRIPTION; GROWTH REGULATION; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; TSC2 GENE; TUBEROUS SCLEROSIS COMPLEX 2 GENE; VASCULAR SMOOTH MUSCLE;

ANIMALIA;

EID: 0043245151     PISSN: 03636143     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpcell.00482.2002     Document Type: Article

References (61)

1. Anonymous. Identification and characterization of the tuberous sclerosis gene on chromosome 16. The European Chromosome 16 Tuberous Sclerosis Consortium. Cell 75: 1305-1315, 1993.
2. Astrinidis A, Khare L, Carsillo T, Smolarek T, Au KS, Northrup H, and Henske EP. Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis. J Med Genet 37: 55-57, 2000.
3. Berger U, Khaghani A, Pomerance A, Yacoub MH, and Coombes RC. Pulmonary lymphangioleiomyomatosis and steroid receptors. An immunocytochemical study. Am J Clin Pathol 93: 609-614, 1990.
4. Burger AM, Kaur G, Alley MC, Supko JG, Malspeis L, Grever MR, and Sausville EA. Tyrphostin AG17 [(3,5-di-tertbutyl-4-hydroxybenzylidene)-malononitrile] inhibits cell growth by disrupting mitochondria. Cancer Res 55: 2794-2799, 1995.
5. Burroughs KD, Fuchs-Young R, Davis B, and Walker CL. Altered hormonal responsiveness of proliferation and apoptosis during myometrial maturation and the development of uterine leiomyomas in the rat. Biol Reprod 63: 1322-1330, 2000.
6. Carsillo T, Astrinidis A, and Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 97:6085-6090, 2000.
7. Davis RJ. The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 268: 14553-14556, 1993.
8. Denhardt DT. Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling. Biochem J 318: 729-747, 1996.
9. Dickson RB and Lippman ME. Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev 8: 29-43, 1987.
10. Espinosa E, Oemar BS, and Luscher TF. 17Beta-estradiol and smooth muscle cell proliferation in aortic cells of male and female rats. Biochem Biophys Res Commun 221: 8-14, 1996.
11. Farhat MY, Lavigne MC, and Ramwell PW. The vascular protective effects of estrogen. FASEB J 10: 615-624, 1996.
12. Filardo EJ, Quinn JA, Bland KI, and Frackelton AR Jr. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via transactivation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 14: 1649-1660, 2000.
13. Finlay GA, Thannickal VJ, Fanburg BL, and Paulson KE. Transforming growth factor-beta1-induced activation of the ERK pathway/activator protein-1 in human lung fibroblasts requires the autocrine induction of basic fibroblast growth factor. J Biol Chem 275: 27650-27656, 2000.
14. Fischer-Dzoga K, Wissler RW, and Vesselinovitch D. The effect of estradiol on the proliferation of rabbit aortic medial tissue culture cells induced by hyperlipemic serum. Exp Mol Pathol 39: 355-363, 1983.
15. Gaine SP and Rubin LJ. Primary pulmonary hypertension. Lancet 352: 719-725, 1998.
16. Gao X and Pan D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev 15: 1383-1392, 2001.
17. Gomez MR. Tuberous Sclerosis. New York: Raven, 1988.
18. Gray K, Eitzman B, Raszmann K, Steed T, Geboff A, McLachlan J, and Bidwell M. Coordinate regulation by diethylstilbestrol of the platelet-derived growth factor-A (PDGF-A) and -B chains and the PDGF receptor alpha- and beta-subunits in the mouse uterus and vagina: potential mediators of estrogen action. Endocrinology 136: 2325-2340, 1995.
19. Greene GL and Press MF. Structure and dynamics of the estrogen receptor. J Steroid Biochem 24: 1-7, 1986.
20. Howe SR, Gottardis MM, Everitt JI, Goldsworthy TL, Wolf DC, and Walker C. Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. Am J Pathol 146: 1568-1579, 1995.
21. Howe SR, Gottardis MM, Everitt JI, and Walker C. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo. Endocrinology 136: 4996-5003, 1995.
22. Karas RH, Patterson BL, and Mendelsohn ME. Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 89: 1943-1950, 1994.
23. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, and Chambon P. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491-1494, 1995.
24. Kobayashi T, Hirayama Y, Kobayashi E, Kubo Y, and Hino O. A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer. Nat Genet 9: 70-74, 1995.
25. Kovalenko M, Gazit A, Bohmer A, Rorsman C, Ronnstrand L, Heldin CH, Waltenberger J, Bohmer FD, and Levitzki A. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res 54: 6106-6114, 1994.
26. Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, el-Hashemite N, and Onda H. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet 11: 525-534, 2002.
27. Lange CA, Richer JK, Shen T, and Horwitz KB. Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways. J Biol Chem 273: 31308-31316, 1998.
28. Levitzki A, Gazit A, Osherov N, Posner I, and Gilon C. Inhibition of protein-tyrosine kinases by tyrphostins. Methods Enzymol 201: 347-361, 1991.
29. Logginidou H, Ao X, Russo I, and Henske EP. Frequent estrogen and progesterone receptor immunoreactivity in renal angiomyolipomas from women with pulmonary lymphangioleiomyomatosis. Chest 117: 25-30, 2000.
30. Lou D, Griffith N, and Noonan DJ. The tuberous sclerosis 2 gene product can localize to nuclei in a phosphorylation-dependent manner. Mol Cell Biol Res Commun 4: 374-380, 2001.
31. Lu Q, Ebling H, Mittler J, Baur WE, and Karas RH. MAP kinase mediates growth factor-induced nuclear translocation of estrogen receptor alpha. FEBS Lett 516: 1-8, 2002.
32. Manning DB, Tee AR, Logsdon MN, Blenis J, and Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway. Mol Cell 10: 151-162, 2002.
33. Menchine M, Emelin JK, Mischel PS, Haag TA, Norman MG, Pepkowitz SH, Welsh CT, Townsend JJ, and Vinters HV. Tissue and cell-type specific expression of the tuberous sclerosis gene, TSC2, in human tissues. Mod Pathol 9: 1071-1080, 1996.
34. Mendelsohn ME. Nongenomic, ER-mediated activation of endothelial nitric oxide synthase: How does it work? What does it mean? Circ Res 87: 956-960, 2000.
35. Mendelsohn ME and Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 340: 1801-1811, 1999.
36. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, and Auricchio F. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 15: 1292-1300, 1996.
37. Moss J, Avila NA, Barnes PM, Litzenberger RA, Bechtle J, Brooks PG, Hedin CJ, Hunsberger S, and Kristof AS. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med 164: 669-671, 2001.
38. Murthy V, Haddad LA, Smith N, Pinney D, Tyszkowski R, Brown D, and Ramesh V. Similarities and differences in the subcellular localization of hamartin and tuberin in the kidney. Am J Physiol Renal Physiol 278: F737-F746, 2000.
39. Ohori NP, Yousem SA, Sonmez-Alpan E, and Colby TV. Estrogen and progesterone receptors in lymphangioleiomyomatosis, epithelioid hemangioendothelioma, and sclerosing hemangioma of the lung. Am J Clin Pathol 96: 529-535, 1991.
40. Ohtsuka T, Shimizu K, Yamamori B, Kuroda S, and Takai Y. Activation of brain B-Raf protein kinase by RaplB small GTP-binding protein. J Biol Chem 271: 1258-1261, 1996.
41. Pizon V, Lerosey I, Chardin P, and Tavitian A. Nucleotide sequence of a human cDNA encoding a ras-related protein (raplB). Nucleic Acids Res 16: 7719, 1988.
42. Posner I, Engel M, Gazit A, and Levitzki A. Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program. Mol Pharmacol 45: 673-683, 1994.
43. Potter CJ, Huang H, and Xu T. Drosophila Tscl functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 105: 357-368, 2001.
44. Pourreau-Schneider N, Berthois Y, Gandilhon P, Cau P, and Martin PM. Early alterations at the plasma membrane of breast cancer cell lines in response to estradiol and hydroxytamoxifen. Mol Cell Endocrinol 48: 77-88, 1986.
45. Powell CE, Soto AM, and Sonnenschein C. Identification and characterization of membrane estrogen receptor from MCF7 estrogen-target cells. J Steroid Biochem Mol Biol 77: 97-108, 2001.
46. Sartor CI, Dziubinski ML, Yu CL, Jove R, and Ethier SP. Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. Cancer Res 57: 978-987, 1997.
47. Shanker G, Sorci-Thomas M, and Adams MR. Estrogen modulates the inducible expression of platelet-derived growth factor mRNA by monocyte/macrophages. Life Sci 56: 499-507, 1995.
48. Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, and Henske EP. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 62: 810-815, 1998.
49. Speir EC and Cannon RO. Role of estrogen in smooth muscle growth and function. In: LAM and Other Diseases Characterized by Smooth Muscle Cell Proliferation, edited by Moss J. New York: Dekker, 1999, p. 351-373.
50. Strizheva GD, Carsillo T, Kruger WD, Sullivan EJ, Ryu JH, and Henske EP. The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis. Am J Respir Crit Care Med 163: 253-258, 2001.
51. Sullivan EJ. Lymphangioleiomyomatosis: a review. Chest 114: 1689-1703, 1998.
52. Umayahara Y, Kawamori R, Watada H, Imano E, Iwama N, Morishima T, Yamasaki Y, Kajimoto Y, and Kamada T. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J Biol Chem 269: 16433-16442, 1994.
53. Vargas R, Wroblewska B, Rego A, Hatch J, and Ramwell PW. Oestradiol inhibits smooth muscle cell proliferation of pig coronary artery. Br J Pharmacol 109: 612-617, 1993.
54. Watters JJ, Campbell JS, Cunningham MJ, Krebs EG, and Dorsa DM. Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. Endocrinology 138: 4030-4033, 1997.
55. Weiser-Evans MC, Schwartz PE, Grieshaber NA, Quinn BE, Grieshaber SS, Belknap JK, Mourani PM, Majack RA, and Stenmark KR. Novel embryonic genes are preferentially expressed by autonomously replicating rat embryonic and neointimal smooth muscle cells. Circ Res 87: 608-615, 2000.
56. Weisz A, Cicatiello L, Persico E, Scalona M, and Bresciani F. Estrogen stimulates transcription of c-jun protooncogene. Mol Endocrinol 4: 1041-1050, 1990.
57. Wienecke R, Konig A, and DeClue JE. Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific Rap1GAP activity. J Biol Chem 270: 16409-16414, 1995.
58. Yeung RS, Xiao GH, Jin F, Lee WC, Testa JR, and Knudson AG. Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. Proc Natl Acad Sci USA 91: 11413-11416, 1994.
59. York RD, Yao H, Dillon T, Ellig CL, Eckert SP, McCleskey EW, and Stork PJ. Rap1 mediates sustained MAP kinase activation induced by nerve growth factor. Nature 392: 622-626, 1998.
60. Yoshida Y, Kawata M, Miura Y, Musha T, Sasaki T, Kikuchi A, and Takai Y. Microinjection of smg/rap1/Krev-1 p21 into Swiss 3T3 cells induces DNA synthesis and morphological changes. Mol Cell Biol 12: 3407-3414, 1992.
61. Zhang L, Kharbanda S, Hanfelt J, and Kern FG. Both autocrine and paracrine effects of transfected acidic fibroblast growth factor are involved in the estrogen-independent and antiestrogen-resistant growth of MCF-7 breast cancer cells. Cancer Res 58: 352-361, 1998.